Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Structure Therapeutics Inc. - American Depositary Shares (NQ: GPCR )

38.12 +0.68 (+1.82%)
Streaming Delayed Price Updated: 10:53 AM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 119,337
Open 37.58
Bid (Size) 37.93 (4)
Ask (Size) 38.15 (2)
Prev. Close 37.44
Today's Range 37.21 - 38.31
52wk Range 25.57 - 75.02
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon.
Eli Lilly is still a smart pick, but these two stocks could grow more in the near term. 
Via The Motley Fool
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
The Nasdaq tumbled amid chip woes. 
Via Investor's Business Daily

Performance

YTD
-5.62%
-5.62%
1 Month
-16.35%
-16.35%
3 Month
+5.83%
+5.83%
6 Month
-8.43%
-8.43%
1 Year
+8.79%
+8.79%

More News

Read More
Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
Via Benzinga
ASML Reports Q2 Results, Joins Spirit Airlines And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Peering Into Structure Therapeutics's Recent Short Interest
Via Benzinga
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in July 2024
Via InvestorPlace
Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
Via MarketBeat
Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
Via MarketBeat
Exposures Product Safety
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
Via MarketBeat
The 3 Smartest Biotech Stocks to Buy With $5K Right Now
Via InvestorPlace
Could Structure Therapeutics Become the Next Novo Nordisk?
Via The Motley Fool
Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
Via Investor's Business Daily
Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?
Via The Motley Fool
Skye Bioscience Pivots To Obesity After Glaucoma Flop; Shares Plummet
Via Investor's Business Daily
Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy?
Via The Motley Fool
Top Names Performance Update - Saturday, June 8
Via Talk Markets
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
Via Talk Markets
Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering
From Structure Therapeutics Inc.
Via GlobeNewswire
The 3 Most Undervalued Biotech Stocks to Buy in June 2024
Via InvestorPlace
Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics' Obesity Candidate Is ' Very Competitive' To Eli Lilly's Orforglipron, Analyst Says
Via Benzinga
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Structure Therapeutics Stock Skyrockets To Six-Month High On Compelling Weight-Loss Drug Results
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.